Skip to main content
DAEWOONG PHARMA logo

DAEWOONG PHARMA — Investor Relations & Filings

Ticker · 069620 ISIN · KR7069620003 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2026-06-01 Governance Information
Country KR South Korea
Listing KO 069620

About DAEWOONG PHARMA

http://crm.daewoong.co.kr/eng/main

Daewoong Pharma is an R&D-centric pharmaceutical company specializing in the development, manufacturing, and commercialization of medical products. The company's portfolio encompasses prescription drugs, with a focus on gastrointestinal and endocrine therapies, alongside biologics, healthcare products, and active pharmaceutical ingredients (APIs). A core tenet of its business model is 'Open Collaboration,' actively seeking partnerships with academic and industry entities to foster innovation. Daewoong Pharma's research efforts are directed towards breakthrough therapies, utilizing advanced drug delivery technologies and expertise in biologics. The company also offers integrated formulation and manufacturing services, supporting partners from initial development to commercial production.

Recent filings

Filing Released Lang Actions
기업지배구조보고서공시
Governance Information Classification · 95% confidence The document is titled "기업지배구조보고서 신고서" (Corporate Governance Report) and provides detailed disclosures on governance policies, board composition, internal control procedures, shareholder meeting protocols, and compliance with governance principles. It is a full governance report (over 80,000 characters), not merely an announcement, and it addresses internal rules and board structure. This matches the Governance Information category (CGR).
2026-06-01 Korean
투자판단관련주요경영사항 (엔블로젬(Envlozem)의 국내 품목허가 신청)
Regulatory Filings Classification · 85% confidence The document is a regulatory announcement by Daewoong Pharmaceutical regarding the submission of a new drug (Envlozem) for domestic approval. It contains no financial statements, management changes, or earnings data, nor is it presenting an actual report like a 10-K or interim report. It is a general regulatory notice (‘투자판단 관련 주요경영사항’ under Korean disclosure rules), fitting the fallback category for miscellaneous regulatory filings.
2026-05-26 Korean
투자판단관련주요경영사항 (엔블로정(Envlo) 0.3mg 멕시코 품목허가 승인)
Regulatory Filings Classification · 75% confidence The document is a Korean-language disclosure titled “투자판단 관련 주요경영사항” reporting the approval of a pharmaceutical product license by Mexico’s COFEPRIS. It is a material event/regulatory announcement for investors, not an annual or interim financial report, not a board change, earnings release, dividend notice, M&A filing, or any other specific category. It therefore falls under the generic “Regulatory Filings” category (RNS).
2026-05-26 Korean
투자판단관련주요경영사항 (비만치료용 세마글루타이드(4주 장기지속형 주사제) 기술도입 계약 체결)
Regulatory Filings Classification · 91% confidence The document is a Korean regulatory disclosure of a major contract for technology licensing (Semaglutide obesity treatment) under ‘투자판단 관련 주요경영사항’. It does not contain full financial statements or management discussion, nor is it an earnings release, annual/interim report, proxy, or other specific category. It is a general corporate announcement mandated by regulation, fitting the fallback category “Regulatory Filings (RNS)”.
2026-05-21 Korean
[기재정정]투자판단관련주요경영사항 (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)
Regulatory Filings Classification · 75% confidence The document is a Korean regulatory disclosure (“투자판단 관련 주요경영사항”) and subsequent correction notice about succession of contract rights. It does not contain financial statements, earnings highlights, governance charters, or share transactions, nor is it announcing a dividend, proxy, or M&A of the company itself. It is a routine compliance filing of a material business event. Therefore it falls into the fallback category Regulatory Filings (RNS).
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서 (제25기 1분기)” covering the period 2026-01-01 to 2026-03-31. It contains full business descriptions, financial results, segment disclosures, credit ratings, capital changes, and detailed narrative and quantitative data typical of a quarterly financial report. It is not a short notice or announcement of publication, and it includes substantive financial statements and analysis. Thus it is an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.